This week, 5 Health Care Equipment & Supplies stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).
ResMed Inc. (RMD) earns a B this week, jumping up from last week’s grade of C. ResMed Inc. develops, manufactures and distributes medical equipment for treating, diagnosing and managing sleep-disordered breathing and other respiratory disorders. The company also gets A’s in return on equity. For more information, get Portfolio Grader’s complete analysis of RMD stock.
Cynosure, Inc. Class A (CYNO) boosts its rating from a B to a A this week. Cynosure, Inc. Class A develops, manufactures, and markets aesthetic treatment systems to the dermatology, plastic surgery, and general medical markets. The company also gets A’s in sales growth and earnings surprise. For more information, get Portfolio Grader’s complete analysis of CYNO stock.
Orthofix International NV’s (OFIX) ratings are looking better this week, moving up to a A from last week’s B. Orthofix International NV is a global medical device company offering a line of surgical and non-surgical products mainly in the spine, orthopedics, sports medicine and vascular market sectors. The company also gets A’s in earnings revisions, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of OFIX stock.
This is a strong week for Span-America Medical Systems, Inc. (SPAN). The company’s rating climbs to B from the previous week’s C. Span-America Medical Systems, Inc. manufactures and distributes a variety of therapeutic support surfaces and related products made from polyurethane and other foam products for the medical, consumer and industrial markets. The company also gets A’s in free cash flow. For more information, get Portfolio Grader’s complete analysis of SPAN stock.
The rating of Cerus Corporation (CERS) moves up this week, rising from a C to a B. Cerus Corporation is a biomedical products company engaged in the development and commercialization of the INTERCEPT Blood System. For more information, get Portfolio Grader’s complete analysis of CERS stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.